Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell 30 senescence, a phenotype that are not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism responsible for palbociclib-induced senescence, we performed thermal proteome profiling of MCF7 breast cancer cells. In addition to affecting known CDK4/6 targets, palbociclib induces a thermal stabilization of the 20S proteasome, despite not directly binding to it. We further show that palbociclib 35 treatment increases proteasome activity independently of the ubiquitin pathway. This leads to cellular senescence which can be counteracted by proteasome inhibitors.
Introduction
The two closely related cyclin-dependent kinases CDK4 and CDK6 together with their 55 binding partners cyclin D1, D2, D3 are key regulators of growth and cell proliferation.
The main mechanism by which CDK4/6-cyclin D complexes drive cell cycle progression is through phosphorylation of the retinoblastoma protein (RB1) and related p107 and p130 proteins, which are among the few known CDK4/6 substrates 1 . The phosphorylation of RB1 drives cell cycle progression from G1 to S phase by allowing 60 E2F transcription factor to induce coordinated transcription of genes required for DNA synthesis and cell cycle progression. Nonetheless, cyclin D and CDK4/6 are not universally required for cell cycle progression in most cell types during development 2 .
Breast cancer is the most common cancer in women with close to two million cases per year globally. CDK4/6 inhibition has been recognized to have therapeutic 65 potential in estrogen receptor positive (ER+) breast cancers, which constitute up to 75% of all breast cancers. In breast tissue, the CDK4/cyclin D1 axis appears critical for cancer initiation, as demonstrated using animal models and analysis of human breast cancer specimens [3] [4] [5] [6] . In addition, CDK4/cyclin D inhibition may be additionally beneficial for the treatment of human epidermal growth factor receptor 2 (HER2) and 70 RAS driven breast cancers 7, 8 and potentially many other cancers because cyclin D1 displays most frequent somatic copy number aberrations of all cancer genes 9 .
Palbociclib (PD-0332991/Ibrance) is a potent and selective CDK4/6 inhibitor, based on analysis of 36 other kinases tested 10, 11 . In cell models, palbociclib displays preferential activity in ER + as well as human epidermal growth factor receptor 2 75 (HER2) amplified cell lines 12 . In a recent phase 3 trial, the combinatory treatment with palbociclib and fulvestrant, a selective estrogen receptor downregulator, more than doubled the median progression-free survival as compared with fulvestrant alone 13, 14 .
While broader specificity CDK inhibitors have performed poorly in clinical trials, it is not entirely clear why a selective CDK4/6 inhibitor displays such a remarkable 80 therapeutic response 15 . In addition to the blockade of cancer cell proliferation, palbociclib also induces senescence 1 and displays other unexpected responses such as reduction of tumor volume without inducing apoptosis 3 . Many RB1-deficient breast cancer cells display reduced DNA replication in response to palbociclib 16 and reduced levels of phosphorylated RB1 alone do not explain the oncosupressive effects of 85 palbociclib, at least in liposarcoma patients where such data are available 17 . Similarly, the palbociclib mediated growth inhibition cannot be fully recapitulated by knockdown of CDK4/6 in breast cancer cells 18 . Thus, while the RB1 pathway is clearly important for CDK4/6 mediated cell cycle progression, the therapeutic response to palbociclib potentially includes additional CDK4/6 or RB1 independent activities. Consistently, 90 some of the cellular responses to palbociclib, such as senescence, have been reversed or augmented by knockdowns of seemingly unrelated proteins 19, 20 , suggesting that the mode of action of palbociclib is more complex than previously appreciated. Palbociclib is therefore likely to have unanticipated, clinically relevant targets beyond cell cycle inhibition. Furthermore, clinical trials with palbociclib have evaluated the role of 95 possible biomarkers, but for example gain of cyclin D1, loss of p16, PI-3 kinase mutations or hormone-receptor expression level are not predictive of the treatment response 13, 21 . Thus, there is an urgent need to identify biomarkers that could predict the patient population who would benefit most from palbociclib. Cellular thermal shift assay (CeTSA) has recently emerged as a novel method 100 to identify drug engagement with target proteins in live cells [22] [23] [24] [25] [26] . This method is based on observing the changes in the thermal stability of a protein, which may be due to direct drug binding, drug-induced conformational changes, binding to other cellular components or post-translational modifications such as phosphorylation. When combined with mass spectrometry, the thermal stability changes in proteins can be 105 quantified using a quantitative proteomic approach, holding great promise for identifying drug targets in live cells 26, 27 .
Here we apply mass spectrometry-based cellular thermal shift assay (MS-CeTSA) also known as Thermal Proteome Profiling to study the effects of palbociclib in MCF7 breast cancer cells, and identify proteasome as a downstream target of 110 palbociclib. Palbociclib reduces the association of proteasomal accessory protein ECM29 with the proteasome resulting in enhanced proteolysis. Consistent with the notion that proteasome activation is part of the mode of action for palbociclib, inhibition of proteasome suppresses the cell cycle and senescence phenotypes induced by palbociclib. Together, these results show that thermal proteome profiling can be used 115 to discover novel and unexpected drug responses with potential implications to clinical research.
Results 120

Thermal proteome profiling in MCF7 cells
We performed thermal proteome profiling in MCF7 cells, an ER + and HER2cell line with sensitivity to palbociclib 12 . Palbociclib was used at 10 µM concentration in order to ensure a complete saturation of ligand binding, which maximizes the shift in detected 125 protein denaturation temperature (Tm) [22] [23] [24] [25] [26] . While a 10 µM concentration of palbociclib is higher than the typical IC50 for long term growth inhibition in cell culture, such concentrations are present in tumors in preclinical mouse models 28 . MCF7 cells were treated with palbociclib or vehicle (H2O) in triplicates for 1h and incubated at temperatures ranging from 37°C to 65°C (Fig. 1a) . Heat aggregated proteins were 130 removed by centrifugation and soluble proteins were analyzed by multiplexed quantitative mass spectrometry using isotopically labelled tandem mass tags.
Typical data normalization approaches are not easily applicable for thermal proteome profiling data because the total amount of soluble protein declines with temperature. We previously described that the accuracy of Western blot based cellular 135 thermal shift assay is improved by normalization to thermally stable proteins, such as superoxide dismutase 1 (SOD1) 22 . When equal amount of protein is analyzed by mass spectrometry for each temperature point, thermally stable proteins display increased abundance with temperature in the raw data ( Fig. 1a, middle) . We used a set of 32 identified, abundant and thermally stable proteins for normalization of the mass 140 spectrometry data ( Supplementary Table 1 ). This single-step normalization improved the data quality substantially, reducing the median standard error of the denaturation temperature for the measured proteome from 1.1°C to 0.6°C (Supplementary Fig. 1a ).
Our analysis quantified 5515 proteins with high confidence. For 3707 of these, we could obtain high quality thermal denaturation curves ( Supplementary Table 2 ). 145
The remaining proteins with poorer quality thermal denaturation curves were enriched for membrane proteins and mitochondrial proteins as shown before 26 or displayed atypical thermal denaturation profiles (see Supplementary Fig. 1b for examples). A global denaturation profile of the MCF7 proteome indicated a denaturation catastrophe at 49°C (Fig. 1a, right) , consistent with the cellular "thermal death point" of mesophiles 150 29 and the thermal stability of the erythroleukemia K562 proteome 26 (Supplementary   Fig. 2 ).
We next analyzed how palbociclib affects thermal stability of proteins, first focusing on protein kinases. Palbociclib increased thermal stability (Tm describes the difference between the palbociclib treatment and control melting temperatures) of its 155 main targets CDK4 and CDK6, as expected ( Fig. 1b, c) . While the magnitude of the Tm does not directly indicate binding affinity 23 , CDK4 displayed the second strongest Tm of all kinases, exceeded only by phosphofructokinase (PFKL, liver isoform), a recently identified CDK6 substrate 30 (Fig. 1d ). Tm of CDK6 was the 8 th strongest.
The mechanistic target of rapamycin (MTOR) was also among the kinases with high 160 Tm value. We also observed thermal destabilization, a decrease in Tm, which could result from indirect drug effects 27 , ligand binding to partially unfolded state 31 or conformational changes that destabilize the protein structure. The most destabilized kinases by palbociclib included CDK7 and AKT1 ( Fig. 1d, Supplementary Fig. 3a,   b ). Overall, we observed substantial overlap with previously identified palbociclib 165 binding kinases 32 (Fig. 1e ) and previously measured palbociclib inhibitory activity against 22 kinases in vitro (Supplementary Fig. 3c) , indicating high quality of our dataset. While, our data indicate that palbociclib may affect multiple pathways including the PI3K/AKT/MTOR signaling pathway ( Supplementary Fig. 3d ), the PI3K/AKT/MTOR pathway inhibition is weak and evident only at higher drug 170 concentrations ( Supplementary Fig. 3e, f, g) . These findings are consistent with previous observations that CDK4/6 inhibition can partially attenuate MTORC1 activity 8 .
Palbociclib activates the 26S proteasome 175
To gain a global insight into palbociclib-induced cellular changes, we analyzed what protein complexes were affected by palbociclib. To visualize the separation from non-affected complexes, we plotted changes in both Tm and S, a parameter related to the change in the slope of the melting curve (see methods). This analysis identified complexes involved in DNA replication (RAD17-RFC and PCNA-CHL12-RFC2-5 180 complexes), chromatin modification (E2F-6 complex, STAGA and HMGB1-2 complex) ( Fig. 2a) . In addition, we identified the MTORC2 complex and the 20S proteasome. As proteasomal activity is essential for the ordered progression through the cell cycle 33 , and as the proteasome is regulated by MTOR signaling 34 and is a potent drug target in human cancers 35 , we decided to study the proteasome in more 185 detail. The complete 26S proteasome is comprised of the core catalytic 20S proteasome and the regulatory 19S lid. Unexpectedly, all components in the 20S proteasome displayed an increase in Tm upon palbociclib treatment, whereas the 19S subunits were largely unaffected ( Fig. 2b) .
To understand the physiological impact that palbociclib has on the proteasome, 190 we first measured proteasomal activity in MCF7 cells using a fluorescent peptide substrate Me4BodipyFL-Ahx3Leu3VS 36 . After 1h treatment, palbociclib activated the degradation of the peptide substrate in a dose dependent manner ( Fig. 2c) , whereas MG-132, a proteasomal inhibitor abolished substrate degradation. Another CDK4/6 inhibitor, ribociclib, also increased proteasomal substrate degradation, although to a 195 lesser extent. The proteasomal activation persisted when cells were incubated with palbociclib for 30h and the level of proteasomal activation with 1 µM palbociclib was comparable to that observed with a known proteasomal activator, the MTOR inhibitor Torin-1 at 0.1 µM concentration ( Fig. 2d) . Note that 1 µM concentration of palbociclib is lower than the typical range (1.4 µM -4.8 µM) seen in tumor xenografts after treating 200 mice with 10 mg/kg palbociclib 28 . Palbociclib also activated the proteasome in T47D and HeLa cells ( Supplementary Figs. 4a and 4b ) indicating that this is not a cell type specific effect of the drug.
Activity changes observed with peptide substrates do not necessarily reflect changes in proteasomal activity towards protein substrates. We thus examined 205 palbociclib effects on proteasomal activation using the ubiquitin G76V -GFP biosensor 37 .
30h Palbociclib treatment of HeLa cells expressing Ub G76V -GFP resulted in a major reduction in GFP signal, starting with submicromolar doses, consistent with proteasomal activation ( Fig. 2e) . To verify that palbociclib-induced GFP degradation was specific for protein degradation, and not due to changes in protein synthesis, we 210 treated Ub G76V -GFP expressing cells simultaneously with palbociclib and protein synthesis inhibitor cycloheximide (CHX) or proteasome inhibitor MG-132. Palbociclib increased protein degradation even in the presence of CHX, but not in the presence of MG-132 ( Fig. 2f) . Increased protein degradation in the presence of CHX was also seen with ribociclib, a structurally similar CDK4/6 inhibitor ( Fig. 2f) . 215
We also examined if these results could be explained by increased autophagy, as palbociclib was recently shown to activate autophagy in specific cancer cell lines 18 .
However, Western blot analysis of SQSTM1/p62 and LC3A/B protein levels in MCF7 cells did not reveal any significant increase of autophagy to be caused by palbociclib ( Supplementary Fig. 4c, d) . Finally, we induced protein aggregation in cells using the 220 proteasome inhibitor MG-132 and observed that palbociclib can enhance the clearance of aggregated proteins in a proteasome dependent manner when MG-132 is washed out ( Supplementary Fig. 4e ).
Palbociclib induces polyubiquitin chains degradation without activating the whole 225
ubiquitin-proteasome pathway
To validate that palbociclib affects proteasomal degradation globally, we examined the total levels of ubiquitinated cellular proteins by Western blot. This revealed that 1 µM palbociclib treatment reduced the overall level of ubiquitin conjugated proteins in MCF7 cells ( Figs. 2g and 2h ) without changing the 20S 230 proteasome levels ( Fig. 2g ). To confirm that the observed reduction in ubiquitin conjugates is related to polyubiquitin chains that are targeted to proteasomal degradation 38 , we treated MCF7 cells with 1 µM palbociclib for 10 h in the presence or absence of the proteasome inhibitor bortezomib. We then enriched total polyubiquitin and analyzed the linkages by targeted parallel reaction monitoring (PRM) 235 mass spectrometry 39 . This analysis confirmed that amounts of K48 chains, as well as the K6, K29 and K63 chains, were significantly reduced upon palbociclib treatment and this reduction was dependent on proteasomal activity ( Fig. 3) . Note that the BRCA1/BARD1 ubiquitin E3 ligase 38 generates K6 chains and thus palbociclib dependent reduction of K6 chains could be relevant for BRCA1 mutant breast cancers. 240
If palbociclib activates the whole ubiquitin-proteasome pathway, palbociclib treatment should increase the levels of ubiquitin chains when ubiquitin breakdown is blocked by proteasome inhibition. However, this was not the case, as none of the ubiquitin chain types displayed increased levels when cells were co-treated with palbociclib and bortezomib ( Fig. 3) . When the experiments were done with the 245 proteasome inhibitor MG-132, similar conclusions were reached ( Supplementary Fig.   5 ). However, it is worth noticing that bortezomib and MG-132 did not induce fully identical ubiquitin levels, most likely due to the lower specificity of MG-132.
Altogether, these data show that palbociclib does not cause increases in protein ubiquitination and thus the palbociclib-induced protein degradation is due to a specific 250 activation of the proteasome.
Palbociclib activates the proteasome through an indirect, ECM29 mediated mechanism
We next asked if the proteasomal activation is a result of direct interaction 255 between palbociclib and the proteasome or if it is mediated by other cellular proteins.
In vitro proteasome activity assays indicated that the increased proteasome activity was not due to direct palbociclib effect on 20S proteasome ( Fig. 4a ). Next, we examined the primary targets of palbociclib and ribociclib, CDK4 and CDK6. Knockdown of CDK4 induced a negligible increase in proteasome activity in HeLa and MCF7 cells 260 ( Fig. 4b) . Knockdown of CDK6 had no effect and combined CDK4 and CDK6 knockdown was similar to CDK4 alone ( Fig. 4b) . Proteasome activation was also independent of RB1, the best-established phosphorylation target of CDK4 and CDK6 ( Fig. 4c) . We also examined if proteasomal activation by palbociclib occurs at a certain phase of the cell cycle by co-staining MCF7 cells with the fluorescent peptide substrate 265 and a DNA binding dye. Palbociclib increased proteasome activity similarly in G1, S and G2/M phases indicating cell cycle independent activation (Supplementary Fig.  4f ). Altogether, these data suggest that palbociclib affects proteasome in a CDK4, CDK6 and cell cycle independent manner. Palbociclib and ribociclib have overlapping off-target profiles 32 making it 270 possible that a previously unappreciated target(s) mediates the proteasomal activation.
Furthermore, as MTOR is a known regulator of proteasome 34 , the weak inhibition of PI3K/AKT/MTOR signaling could be involved in the proteasome activation. To gain insight in to the mechanism of how palbociclib activates the proteasome, we immunoprecipitated proteasomes with anti-4 20S subunit antibody after 4h treatments 275 with palbociclib or the MTOR inhibitor Torin-1 and used quantitative mass spectrometry to compare changes in proteasomal protein levels and in phosphorylation sites in proteasomal proteins to untreated controls ( Fig. 4d and Supplementary Fig.   6a ). The identified phosphosites were largely non-overlapping between palbociclib and Torin-1, suggesting independent mechanisms for proteasome activation 280 ( Supplementary Fig. 6b and Supplementary table 5 ). Approximately half of the phosphosites in the pulldown from palbociclib treated cells were proline-directed and thus potential substrates for MAPK and CDKs 40 . The remaining sites were highly enriched for acidic residues after the phosphorylated amino acid residue ( Supplementary Fig. 6c ), suggestive of phosphorylation by casein kinase 2, which was 285 identified as a potential palbociclib target ( Fig. 1e) . However, inhibition of casein kinase 2 by quinalizarin (CK2i) (5µM for 2h) did not activate the proteasome, but slightly reduced it ( Supplementary Fig. 6c , right). Thus, although palbociclib may affect both casein kinase 2 and PI3K/AKT/MTOR signaling ( Fig. 1e and Supplementary Fig. 3 ), these mechanisms are unlikely to explain the proteasomal 290 activation by palbociclib.
The lack of strong candidate phosphorylation sites in palbociclib treated cells prompted us to analyze if palbociclib could mediate its effects on proteasome through protein levels. Palbociclib-induced changes on the protein levels were much larger than those induced by Torin-1 ( Fig. 4e ), suggesting that palbociclib, unlike Torin-1, may 295 affect proteasome structure and/or assembly. While many 19S subunits displayed reduced levels in the presence of palbociclib, the proteasome activator complex subunit 3 (PSME3) and the proteasomal scaffold protein ECM29 had the largest palbociclibinduced decline in abundance ( Fig. 4e) . ECM29, a 204 kDa protein, has been reported to inhibit proteasomal activity in yeast 41 , possibly by disassembling the proteasome 42 . 300
We proceeded to examine if palbociclib-induced proteasomal activation could be mediated by ECM29. Consistent with the role of ECM29 as a proteasomal inhibitor 41 , siRNA mediated depletion of ECM29 increased proteasomal activity in both MCF7
and HeLa cells (Figures 5a, Supplementary Fig. 7a ). Combining ECM29 knockdown with palbociclib treatment did not result in any further increase in proteasomal activity 305 as measured by both the proteasomal activity probe Me4BodipyFL-Ahx3Leu3VS and Ub G76V -GFP degradation ( Fig. 5a, Fig. 5b and Supplementary Fig. 7a ). Thus, ECM29 is required for the palbociclib-induced proteasomal activity, suggesting that ECM29 mediates the palbociclib-induced proteasome effects.
310
ECM29 is critical for normal cell proliferation
Next, we examined the role of ECM29 in the growth and proliferation of breast cancer cells. We induced loss of ECM29 using CRISPR in MCF7 cells and established a cell line which displayed heterozygous knock-out of ECM29. This cell line displayed extremely slow proliferation ( Fig. 5c ) compared to the parental unaltered cell line. We 315
were not able to create homozygous knockout of ECM29, most likely due to homozygous knockout being lethal for MCF7 cells. Knockdown of ECM29 using siRNA similarly inhibited MCF7 and T47D cell proliferation ( Supplementary Fig.   7b ), confirming that ECM29 is involved in cell proliferation. The ECM29 knockout cells were also much larger and many of the cells stained positively for acidic -320 galactosidase activity, an established marker for cellular senescence (Fig. 5d ). This suggests that ECM29, or the associated proteasome activity, is involved in regulation of cell senescence, a feature previously associated with palbociclib treatment 1, 18 .
ECM29 expression may predict relapse-free survival in breast cancer 325
To characterize the potential role of ECM29 as a mediator of palbociclib effects in breast cancer, we examined the potential breast cancer association of ECM29 through the publicly available gene expression data on relapse-free breast cancer patient survival 43 . Lower expression of ECM29 displayed a marginally longer relapse free survival time when all breast cancer cases were analyzed (hazard ratio (HR) = 1.26, 330 logrank p = 8.5×10 -5 , n = 3554) ( Fig. 5e ). However, lower expression of ECM29 associated with substantially longer survival times in the patient population with HER2 + cancers (HR = 2.37, p = 0.016, n = 168) ( Fig. 5f) . Consistently, CDK4/6 inhibitors have been shown to be effective against HER2 + cancers in animal models 8 . Furthermore, ECM29 expression levels could predict survival benefit in patients receiving endocrine 335 therapy (HR = 1.59, p = 0.00029, n = 999) ( Fig. 5g) . Additional gene expression datasets provided further support for the correlation between low expression levels of ECM29 and longer breast cancer patient survival (Supplementary Fig. 7c ).
Altogether, our data suggests that the expression of ECM29 should be investigated as a potential biomarker to better identify those individuals benefiting from palbociclib 340 alone or in combination with endocrine therapy.
Proteasomal activity is required for palbociclib-induced cellular phenotypes
To gain insight in how increased proteasomal activity could limit breast cancer growth, we examined palbociclib-induced degradation of endogenous proteins in 345 MCF7 cells using Western blotting. A 6h treatment with palbociclib-induced proteasome dependent degradation of 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) (Fig. 6a) , the rate-limiting enzyme of the mevalonate pathway, which is critical for normal cell growth and proliferation 44 . Levels of housekeeping proteins GAPDH and SOD1 were not affected by palbociclib. At a later timepoint (30h), the 350 levels of CDK4 were also reduced by palbociclib in a proteasome-dependent manner ( Fig. 6a, b ), suggesting that in addition to the direct inhibition of CDK4/6 kinase activity, long-term treatment with palbociclib may also inhibit cell proliferation by a positive feedback loop resulting from proteasomal CDK4 degradation.
To understand the role of increased proteasome activity in palbociclib-induced 355 cell cycle arrest, we isolated MCF7 and T47D cells in G1 phase using centrifugal elutriation and treated these cells with palbociclib, bortezomib or both ( Fig. 6c ). Note that we used bortezomib concentrations that do not completely block all proteasomal activity so that cell viability would be maintained (data not shown). Cell cycle analysis showed that palbociclib prevented progression beyond the G1 phase and bortezomib 360 alone induced cell accumulation at G2/M. Unexpectedly, bortezomib, which counteracts the proteasomal activation by palbociclib, could override the palbociclibinduced G1 arrest in both cell lines ( Fig. 6d and Fig. 6e ). Thus, these data suggest that proteasomal activity is required for palbociclib-induced cell cycle arrest. Increased proteasomal activation by palbociclib may be an additional mechanism to ensure the 365 completeness of the G1 arrest.
If the proteasomal activation by palbociclib is involved in some of the cellular phenotypes caused by palbociclib treatment, then resistance to palbociclib should also be seen in the form of lower proteasomal activity. Recently, MCF7 and TD47 cell lines resistant to CDK4 and CDK6 inhibitors have been created 19 , and these cells display 370 normal cell cycle profile and proliferation rate in the presence of palbociclib and ribociclib. We examined the proteasomal activity in these cells and observed that the CDK4/6 inhibitor resistant cells displayed much lower baseline proteasome activity than the wild type cells (Fig. 6f) . Furthermore, when treated with 1 µM palbociclib for 6h, the resistant cells displayed much smaller increase in proteasome activity, even after 375 normalization for the baseline difference ( Fig. 6g) . As the resistant cell lines were obtained by selecting for cells capable of proliferation in the presence of ribociclib 19 , these results link the cell cycle responses of palbociclib/ribociclib to the proteasomal activity of the cell.
Palbociclib has been reported to induce a senescence-like state in multiple cell 380 types 1 , and at least in MCF7 cells this senescence-like state is dependent on seemingly unrelated cellular components, like integrin β3 and TGF beta pathway 20 . We examined the effects of modest proteasome inhibition by bortezomib on the palbociclib-induced senescence-like state in MCF7 cells. Similarly to the partial loss of ECM29 ( Fig. 5d) , Palbociclib (1 µM) treatment significantly increased MCF7 cell size and the activity of 385 senescence associated -galactosidase, while decreasing the levels of Ki-67 ( Figs. 7a,   7b , 7c, 7e, 7f), all common features of senescence. However, all of these effects were largely or completely suppressed by simultaneous treatment with bortezomib (7.5 nM).
We also examined the levels of Ser139 phosphorylated Histone H2A.X (γH2AX), which is a marker of cellular senescence and DNA damage 45 . γH2AX was upregulated 390 by palbociclib treatment and this effect was dependent on proteasomal activity (Fig.  7a, 7d ). While this is consistent with the other senescence markers, it also suggests that palbociclib may have a role in DNA damage accumulation and/or repair, especially as our MS-CeTSA results identified RAD17-RFC and PCNA-CHL12-RFC2-5, which are protein complexes responding to DNA damage as a potential palbociclib targets. 395
Altogether, these results indicate that the proteasomal activation by palbociclib is critical for the induction of a senescence-like state, suggesting that the proteasome activation by palbociclib is part of the drug's mode of action.
Discussion 400
Proteasomal activity must be tightly regulated to maintain cellular homeostasis.
Proteasomal degradation of cyclins and many other cell cycle regulatory proteins is carefully controlled in order to maintain normal cell cycle progression 33 . Consequently, both activators of proteasome (rapamycin analogs) and direct proteasomal inhibitors (bortezomib) have been considered as treatment options in breast cancer. Using the 405 thermal proteome profiling approach, we identify the proteasome as a novel downstream target for the CDK4/6 inhibitor palbociclib. Further functional analyses revealed that palbociclib causes proteasomal activation at least partly by detaching the proteasomal association of EMC29, which normally suppresses proteasome activity.
Similar, albeit less potent, proteasome activation was also observed with ribociclib, a 410 structurally related CDK4/6 inhibitor. Further studies are required to identify the direct targets of palbociclib that mediate the proteasomal disassociation of EMC29, and our thermal proteome profiling datasets are likely to be useful in this. Curiously, the proteasomal activation by palbociclib was not associated with increased protein ubiquitination, and the palbociclib treatment led to a decrease of several ubiquitin chain 415 types in cells. Nonetheless, the palbociclib-induced augmented proteolysis, including degradation of endogenous proliferation related proteins such as HMGCR and CDK4.
Consistently, the proteasome activation by palbociclib seems to be involved in the reduction of cancer cell proliferation and, especially, in the induction of a senescencelike state (Fig. 7g) . 420
Palbociclib has been a highly effective compound in the treatment of patients with advanced ER + and HER2breast cancer 13, 21 . Given that breast cancers constitute up to 15% of all cancer cases and more than 70% of breast cancers are ER + and HER2 -, palbociclib potentially targets the largest population of cancer patients. A major need to be addressed is the identification of the most responsive patient subpopulation. 425
Although further studies are required, analysis of existing mRNA expression data related to breast cancer survival suggests that ECM29 could be a useful biomarker for HER + cancers and those patients receiving endocrine therapy. We observed that palbociclib reduces the proteasomal association of ECM29 which causes a major reduction in cell proliferation. Palbociclib could therefore be more beneficial in the 430 population with high ECM29 levels, which predict poorer relapse-free survival in patients receiving endocrine therapy.
In contrast to recent work where proteasomal inhibition by DYRK2 kinase knockout was shown to reduce cell cycle progression 46 , we find that high proteasomal activity associates with G1 arrest induced by CDK4/6 inhibition, which may lead to 435 senescence. Our finding is consistent with earlier observations in other model systems where inhibition of the ubiquitin-proteasome system may override CDK4/6 mediated G1 arrest 47, 48 . Overall, the current and previous work indicate that the role of the proteasome in cell cycle progression is complex, likely context dependent and, importantly, exploited by cancer cells to promote cell proliferation. Instead of a 440 simplistic view where more proteasomal activity is always better for the cell, it seems that appropriate proteasomal homeostasis is required for the maintenance of cell proliferation. Proteolytic homeostasis that supports proliferation and cancer growth may also be dependent on autophagy, inhibition of which was recently reported to synergize with palbociclib 18 . Preclinical data suggests that palbociclib sensitizes 445 myeloma cells to bortezomib-induced cell death 49 , but our work raises the question of whether proteasome inhibition and palbociclib are a good combination for breast cancer therapy due to their partly antagonist activity. Indeed, proteasomal activators may have therapeutic potential in certain cancers and this is worthy of further preclinical and translational investigation. MCF7 and T47D cells were synchronized to early/mid G1 using centrifugal elutriation, which was carried out as before 44 . Cells were then plated for 3h after which 480 indicated chemicals were added for 15h. Cell cycle distributions were analyzed by propidium iodide staining. 
Antibodies and Western blotting
Thermal profiling sample preparation
Sample preparation was performed similar to the previous protocols 22, 26 with the following modifications. MCF7 cells were trypsinized, washed with PBS and 505 suspended in PBS supplemented with a protease inhibitor cocktail (Sigma-Aldrich).
Suspended cells (2x10 4 cells/µl) were treated with 10 µM Palbociclib or H2O for 1 h at 37ºC with gentle mixing. Each sample was then separated into 10 fractions, each with 5x10 6 cells for thermal profiling. Fractions were heated at the indicated temperatures (37°C to 65°C) for 3 min using an Eppendorf Thermomixer with mixing (500 rpm). 510
Fractions were then incubated for 3 min at room temperature and frozen on dry ice.
Samples were lysed with four freeze-thaw-cycles using dry ice and 35ºC water bath.
Cell lysates were centrifuged at 16000xg for 15 min at 4ºC to separate protein aggregates from soluble proteins. Supernatants were collected and used for mass spectrometry and Western blots. 515
Proteasome activity assays
Live cell proteasome activity was assessed by pretreating cells with the indicated chemicals followed by 1h incubation in the presence of 0.5 µM proteasome activity probe (Me4BodipyFL-Ahx3Leu3VS; BostonBiochem) 36 . After incubation, 520 cells were washed with PBS and analysed by flow cytometry. The specificity of the proteasome activity probe was also validated on a SDS-PAGE gel, where an equal amount of each sample was loaded to assess proteasome staining.
GFP degradation was measured by reverse transfecting HeLa-TREx cells with
the short-lived Ub G76V -GFP 37 , 12h later treating the cells with doxycycline to induce 525 GFP expression and another 12h later adding the indicated chemicals. GFP levels were measured using flow cytometry and the protein degradation % was calculated by normalising the data to control (0% degraded) and negative control without the GFP construct (100% degraded). When examining GFP levels in the absence of protein synthesis, cells were treated with 100 µM cycloheximide at the same time as when 530 chemicals of interest were added.
Proteasome activity towards protein aggregates were also measured using the ProteoStat Aggresome detection reagent (EnzoLifeSciences). MCF7 cells were first treated with control or palbociclib and cultured in the presence of MG-132 for 18h to accumulate protein aggregates. The cells were then washed twice and treated with 535 palbociclib or control. After 4h the protein aggregate levels were measured using flow cytometer according to the supplier's instructions. Data were normalized to that 0% represents the basal level of protein aggregates in a control untreated with MG-132 and that 100% represents the level to which MG-132 increased the protein aggregates.
20S proteasome activity in vitro was assayed as previously described 50 
Cell senescence assays and proliferative markers detection
MCF7 cells were cultured with either 7.5 nM bortezomib, 1 µM palbociclib or both for ten days, with media change every second day. Note that higher concentrations 550 of bortezomib became toxic to the cells in long term (data not shown). For -galactosidase activity, cells were fixed with 4% paraformaldehyde and stained with 0.1% -gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl2 in 40 mM citric acid/sodium phosphate solution, pH 6.0 for overnight at 37ºC. The cells were washed with PBS and imaged using Nikon Eclipse 555 TS100 microscope. For Ki67 and phospho-Histone H2A.X (Ser139) assays, cells were fixed with 4% paraformaldehyde, permeabilized with 0.5 % Triton X-100 for 5 min, washed twice with 5 % BSA in PBS, and stained with antibodies o/n in +4°C. Ki-67 (D3B5) Alexa Fluor 488 conjugate antibody and Phospho-Histone H2A.X (Ser139) (20E3) Alexa Fluor 647 conjugate antibody were obtained from CST (#11880 and 560 #9720, respectively). The following day cells were washes twice with 5 % BSA in PBS and antibody staining levels were analyzed using LSR II flow cytometer from BD Biosciences. The antibody staining was validated using microscopy, for which samples were stained as before, with the exception that the DNA was stained with DAPI after antibody staining, which was followed by two washes with PBS. Cells were imaged 565 with DeltaVision widefield deconvolution microscope in VectaShield mounting media (VectorLabs) using a 60X objective. According to the different temperature points, labelled peptides were combined, acidified with 200 μL of 0.1% TFA (pH  2) and concentrated using the C18 SPE on 595
Immunoprecipitation of proteasomes
Sep-Pak cartridges (Waters).
Hydrophilic Strong Anion Exchange (hSAX) chromatography
TMT labeled peptides were subjected to hydrophilic Strong Anion Exchange (hSAX) fractionation 51 was performed using FTMS3 acquisition in the Orbitrap mass analyser operated at 60,000 resolution, with an AGC target of 100,000 ions and a max injection time of 120 ms. Higher-energy C-trap dissociation (HCD fragmentation) on MS/MS fragments was performed in one-step collision energy of 55% to ensure maximal TMT reporter ion yield and synchronous-precursor-selection (SPS) was enabled to include 10 MS/MS 630 fragment ions in the FTMS3 scan. 
Data processing and quantitative data analysis
655
Data normalization
Stable proteins were classified as those with increasing relative abundance at higher temperatures in control samples. Preliminary analyses showed that those proteins with an average of at least 5 times higher abundance at 59°C compared to 37°C and which were identified by at least 5 unique peptides minimised the standard error in 660 denaturation curve fitting. Keratins were omitted from the list of stable proteins as they could be a contamination from sample handling. The 59°C data point rather than any higher temperature point was used as the identification of stable proteins as it had the minimum standard error of the curve fitting. Mean abundance for the identified 32 stable proteins were calculated for each temperature and the relative abundancies of the 665 proteins at each temperature were divided with the mean abundance for the 32 proteins at the same temperature. For immunoprecipitated proteasomes, protein abundance data was normalized to the total abundance of 20S subunits, excluding the less abundant immunoproteasome subunits.
670
Denaturation curve fitting
For the 5515 proteins quantified by mass spectrometry, only those identified The sigmoid function can be reparameterized to fit for the melting temperature directly, by replacing with ,
This form of the sigmoid curve was fit to all protein profiles using the non-linear least squares method (package 'nls' in R). Each protein was fit ten times with randomized 685 initial parameters to minimize the chance of finding a false local 2 minimum.
To exclude poorly fitting data, Z scores were calculated for the residual mean variation from the curve fitting and included only if |Z score|<3. Finally, we included only proteins where the standard error of Tm was less that median +3 × median average deviation (MAD) for the standard error of Tm. The final list consisted of 3707 proteins. 690
Mass spectrometry analysis of immunoprecipitated proteasome.
Protein extracts from each biological replicates were loaded on NuPAGE 4-12% bis-tris acrylamide gels (Invitrogen). Running of protein was stopped as soon as proteins stacked in a single band, stained with InstantBlue (Expedeon), cut from the gel 695 and digested with trypsin protease, MS Grade (Pierce) as described previously 53 . Mass spectrometry analysis was carried out by LC−MS/MS using similar settings as described above except that samples were measured in "Top Speed" data-dependent acquisition mode. Statistical significance was analysed from the three replicate samples by two-tailed t-test without adjusting for multiple hypothesis testing. Extracts were loaded on NuPAGE 4-12% bis-tris acrylamide. Running of protein was stopped as soon as proteins stacked in a single band, stained with InstantBlue 715 (Expedeon), cut from the gel, reduced with 10 mM TCEP for 10 min at 65°C and digested with trypsin before analysis by mass spectrometry.
Preparation of Ub-AQUA peptide mixtures
Concentrated stocks of isotopically labelled internal standard (heavy) peptides 720 and light synthetic peptides (M1, K6, K11, K27, K29, K33, K48, K63) were purchased from Cell Signaling Technologies). All stock solutions were stored at -80°C, working stock solution of individual peptides were prepared at 25 pmol/µl in 2% ACN, 0,1% FA and used to prepare an experimental mixture consisting of 8 peptides at 1 pmol/µl in 2% ACN, 0.1% FA. The mixtures were frozen at -80°C in triplicate use aliquots for 725 direct addition to samples.
Targeted mass spectrometry of ubiquitin chain types
Absolute analysis of ubiquitin chain types was performed similar to reported previously 55 
Kinase inhibitor data 750
The in vitro activity data for palbociclib were downloaded from http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors.
Kaplan-Meier survival analysis
Kaplan-Meier curves for ECM29 in breast cancer were generated using the 755 KMplot online service (http://www.kmplot.com), which combines publicly available mRNA expression datasets and associated clinical information 43 . The survival was assessed for the whole population and various subpopulations of which HER2 expressing and endocrine therapy receiving patient populations displayed most significant survival benefits. 760 
Figure legends
